DARE vs TPVG vs EVAX vs CODA vs ANIP

For growth investors, Evaxion Biotech A/S (EVAX) is the stronger pick with 125.

8% revenue growth year-over-year, versus -99. 7% for Daré Bioscience, Inc. (DARE). TriplePoint Venture Growth BDC Corp. (TPVG) offers the better valuation at 4. 9x trailing P/E (6. 5x forward), making it the more compelling value choice. Analysts rate Coda Octopus Group, Inc. (CODA) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, TriplePoint Venture Growth BDC Corp.

(TPVG) is the cheapest at 4. 9x versus Coda Octopus Group, Inc. at 32. 2x. On forward P/E, TriplePoint Venture Growth BDC Corp. is actually cheaper at 6. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Coda Octopus Group, Inc. wins at 5. 24x versus TriplePoint Venture Growth BDC Corp. 's 6. 41x.

Over the past 5 years, ANI Pharmaceuticals, Inc.

(ANIP) delivered a total return of +117. 4%, compared to -98. 8% for Evaxion Biotech A/S (EVAX). Over 10 years, the gap is even starker: CODA returned +844. 4% versus EVAX's -99. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Daré Bioscience, Inc.

(DARE) is the lower-risk stock at 0. 48β versus Evaxion Biotech A/S's 1. 29β — meaning EVAX is approximately 168% more volatile than DARE relative to the S&P 500. On balance sheet safety, Coda Octopus Group, Inc. (CODA) carries a lower debt/equity ratio of 1% versus 133% for TriplePoint Venture Growth BDC Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Evaxion Biotech A/S (EVAX) is pulling ahead at 125.

8% versus -99. 7% for Daré Bioscience, Inc. (DARE). On earnings-per-share growth, the picture is similar: ANI Pharmaceuticals, Inc. grew EPS 419. 2% year-over-year, compared to 15. 6% for Coda Octopus Group, Inc.. Over a 3-year CAGR, ANIP leads at 40. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TriplePoint Venture Growth BDC Corp.

(TPVG) is the more profitable company, earning 50. 6% net margin versus -414. 3% for Daré Bioscience, Inc. — meaning it keeps 50. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPVG leads at 77. 9% versus -2396. 9% for DARE. At the gross margin level — before operating expenses — EVAX leads at 99. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Coda Octopus Group, Inc. (CODA) is the more undervalued stock at a PEG of 5. 24x versus TriplePoint Venture Growth BDC Corp. 's 6. 41x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, TriplePoint Venture Growth BDC Corp. (TPVG) trades at 6. 5x forward P/E versus 22. 5x for Coda Octopus Group, Inc. — 16. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TPVG: 49. 4% to $8. 95.

In this comparison, TPVG (17.

1% yield) pays a dividend. DARE, EVAX, CODA, ANIP do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, TriplePoint Venture Growth BDC Corp.

(TPVG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 83), 17. 1% yield). Both have compounded well over 10 years (TPVG: +93. 3%, EVAX: -99. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (DARE (Healthcare) and TPVG (Financial Services) and EVAX (Healthcare) and CODA (Industrials) and ANIP (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: DARE is a small-cap quality compounder stock; TPVG is a small-cap high-growth stock; EVAX is a small-cap high-growth stock; CODA is a small-cap high-growth stock; ANIP is a small-cap high-growth stock. TPVG pays a dividend while DARE, EVAX, CODA, ANIP do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.